Adaptimmune announces appointment of James Noble as Chief Executive Officer

Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced the full-time appointment of James Noble (pictured) as chief executive officer. Mr Noble has been CEO of Adaptimmune since its formation in 2008, but until now has been combining this position with his role as CEO of sister company, Immunocore. He will remain on the Board of Immunocore as a non-executive director.

Dr Jonathan Knowles, currently Executive Chairman of both Adaptimmune and Immunocore, will serve as acting CEO of Immunocore until the company’s board appoints a permanent replacement.

Mr Noble said: “It has been a privilege to oversee the successful expansion of Immunocore through its partnerships and I am delighted to be able to focus on Adaptimmune going forward. The company, with its unique ability to engineer T cell receptors on T cells, is at the forefront of an extraordinarily exciting wave of interest in using the body’s own T cell system to fight cancer. I look forward to building the company up over the coming years”.